Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (MUK seven)
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MUK Seven
- 12 Dec 2017 interim results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 11 May 2016 Status changed from withdrawn prior to enrolment to recruiting.
- 17 Oct 2015 Status changed from suspended to withdrawn prior to enrolment as reported by United Kingdom Clinical Research Network.